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Introduction
Sarcoid uveitis is usually a presumptive diagnosis based on
the simultaneous presence of uveitis and clinicoradio-
graphic or histological findings of sarcoidosis. Mycophe-
nolate mofetil (MMF) is an anti-metabolite, selectively
aimed at affecting lymphocytic action [1, 2]. It has been
proven to be safe and effective in post organ transplant [3]
and seems to have similar efficacy in non-infectious uveitis
[4]. In patients who are corticosteroid resistant or require an
unacceptable dose of corticosteroids to maintain remission,
additional immunosuppression is used, including metho-
trexate, azathioprine, and MMF. We report an uncommon
case of a 34-year-old male of sarcoid uveitis who developed
extensive herpes zoster while on treatment with MMF.
Case report
A 34-year-old male was referred to our hospital with a
history of decreased vision as a result of recurrent bilateral
posterior uveitis. He had repeated recurrences in spite of
systemic corticosteroid therapy. At presentation to us, his
best corrected visual acuity (BCVA) was 6/36, N36 in the
right eye and 6/9, N6 in the left eye. Slit lamp examination
revealed a normal anterior chamber and complicated
cataract in the right eye. On fundus evaluation, both eyes
revealed bilateral disc edema and vitritis and exudates in
the macula in the right eye. He was not a known diabetic.
Laboratory investigations for tuberculosis, collagen vascu-
lar diseases, and other infectious etiologies including
human immunodeficiency virus were within normal limits
except serum angiotension converting enzyme values which
were borderline high. Treatment was initiated with MMF
(2 g/day) [5] along with tapering doses of oral prednisolone
(1 mg/kg/day) in view of the recurrent nature of the uveitis.
The lesions resolved completely with treatment. He under-
went cataract surgery in both eyes 6 months later under cover
of MMF (1 g/day) and systemic corticosteroids. Postopera-
tive period was uneventful. Four months later, he had a
recurrence of fundus lesions and was started on oral
prednisolone (60 mg/day) and his MMF dose was doubled
to 2 g/day by his local ophthalmologist. He came to us within
a month with extensive skin lesions over his right neck and
upper thoracic region which was clinically diagnosed as
herpes zoster (Fig. 1). MMF was stopped and oral acyclovir
(400 mg five times per day) was started. With treatment, the
herpetic lesions resolved and his ocular status was stable with
BCVA 6/12, N12 in the right eye and 6/6, N6 in the left eye.
Discussion
MMF is useful in various ocular inflammatory conditions.
Its advantage is its potent corticosteroid sparing effect and
relatively benign side effects such as gastrointestinal
disturbances, alopecia, and transient leucopenia [6, 7].Our
patient showed a good response to combined treatment with
MMF (2 g/day) and prednisolone (1 g/day). But he
developed extensive herpes zoster after 10 months of
treatment requiring discontinuation of the drug. Opportu-
nistic infections have been rarely reported in sarcoid uveitis
in spite of the immune dysregulation noted in these patients
[8]. Herpes zoster is known to occur in post organ
transplant cases who are on multiple immunosuppressive
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DOI 10.1007/s12348-011-0041-ydrugs usually around the 9th to the 12th month as was seen
in our patient [9]. But a multicentre randomized controlled
trial of MMF in doses of 2–3 g/day for renal transplant
patients did not report even a single case of herpes zoster
[10]. Higher doses of MMF can have an atypical and
disseminated varicella infection [11]. But herpes zoster as
an opportunistic infection with oral steroids is rare and
generally mild and self-limiting [12]. There are no reports
of such extensive herpes lesions in otherwise immunocom-
petent individuals. Thus, in our patient, a cumulative
immunosuppressive effect may have been the reason for
such an extensive involvement with herpes zoster. A
serology done prior to treatment is of no help as patients
with varicella antibodies have also been found to develop
full-borne varicella infection [13]. With discontinuation of
MMF and appropriate anti-viral therapy, the lesions
resolved completely. Studies like SITE study [14] have
shown that the overall risk of opportunistic infections with
the use of long-term immunosuppressives is very low. Our
case highlights the fact that reactivation of herpes zoster
can occur with therapeutic doses of MMF for uveitis in
otherwise healthy immunocompetent adults. It does not
necessarily prove that other such opportunistic infections
may be a possible side effect with MMF treatment. It would
be wise to enlighten the patients regarding this possibility
and allow for early recognition and treatment.
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Fig. 1 Clinical photograph showing extensive herpes zoster involve-
ment in a 35-year-old patient
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